Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1995-6-15
|
| pubmed:abstractText |
There is no known effective salvage chemotherapy for patients with refractory or relapsed urothelial tumors after methotrexate/cisplatin-based regimen. We report the results of a phase II trial with the FIFO regimen that includes from day 1 to 5: fluorouracil 350 mg/m2, folinic acid 20 mg/m2, and ifosfamide 1000 mg/m2, Q4W. Fifteen patients with metastatic measurable urothelial cancer were enrolled in this trial. Previous therapy included M-VAC regimen in 11 patients, CMV regimen in 3 patients, and both regimens in 1 patient. Thirty-one courses were delivered. Toxicity was moderate, including encephalopathy grade 2 in 2 patients and hematological toxicity grade 3 in 2 others. However, an early death occurred on day 1 in a patient who progressed rapidly and died from hepatic insufficiency after initial encephalopathy. No objective response was seen. Twelve patients progressed during FIFO therapy and 3 patients experienced a stable disease. Despite almost encouraging results of fluorouracil and ifosfamide in the literature, their combination according to our schedule is not active in urothelial cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0735-7907
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
276-9
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:7743380-Adrenal Gland Neoplasms,
pubmed-meshheading:7743380-Adult,
pubmed-meshheading:7743380-Aged,
pubmed-meshheading:7743380-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7743380-Bone Neoplasms,
pubmed-meshheading:7743380-Carcinoma, Transitional Cell,
pubmed-meshheading:7743380-Fluorouracil,
pubmed-meshheading:7743380-Hepatic Encephalopathy,
pubmed-meshheading:7743380-Humans,
pubmed-meshheading:7743380-Ifosfamide,
pubmed-meshheading:7743380-Leucovorin,
pubmed-meshheading:7743380-Liver Neoplasms,
pubmed-meshheading:7743380-Lung Neoplasms,
pubmed-meshheading:7743380-Male,
pubmed-meshheading:7743380-Middle Aged,
pubmed-meshheading:7743380-Neoplasm Recurrence, Local,
pubmed-meshheading:7743380-Retroperitoneal Neoplasms,
pubmed-meshheading:7743380-Salvage Therapy,
pubmed-meshheading:7743380-Treatment Failure,
pubmed-meshheading:7743380-Urologic Neoplasms
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
|
| pubmed:affiliation |
Department of Medicine, Institut Gustave Roussy, Villejuif, France.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|